CBD has demonstrated efficacy for drug-resistant epilepsy and shows promise for gut and lung diseases in preclinical studies, but its poor physicochemical properties limit real-world effectiveness without advanced delivery technologies.
Pharmaceutical researchers, CBD product developers, clinicians considering CBD prescriptions, and consumers questioning why CBD products may not work as expected.
What the researchers found
CBD has demonstrated promise for alleviating gut and lung diseases in vitro, and Epidiolex is the only FDA/TGA-approved CBD product. However, CBD's poor water solubility, low oral bioavailability, and extensive first-pass metabolism significantly limit in vivo efficacy. Novel delivery methods including self-emulsifying emulsions, nanoparticles, and microparticles could overcome these barriers.
Why it matters
The gap between CBD's impressive lab results and its underwhelming clinical outcomes is largely a delivery problem. Understanding why CBD works in petri dishes but often fails in people is essential for developing products that actually deliver therapeutic benefit.
The numbers in context
Only one CBD product (Epidiolex) approved by FDA and TGA. CBD shows potential in anxiety, chronic pain, and inflammatory disorders based on animal data. Delivery technologies reviewed: self-emulsifying emulsions, nano and microparticles.
How the study worked
Review of in vitro, in vivo, and clinical research on CBD's therapeutic potential for gastrointestinal and lung diseases, with focus on identified research gaps and novel delivery technologies.
What this study cannot tell us
Review focuses on delivery challenges, which may underemphasize the possibility that CBD's clinical effects are genuinely modest regardless of delivery. Much evidence is preclinical.
How to read the evidence
Comprehensive review of delivery challenges with clear identification of research gaps, though much of the therapeutic evidence reviewed is preclinical.
When this study was published
2024 publication.
The bigger picture
The CBD market generates billions in revenue from products that may deliver subtherapeutic doses due to poor absorption. Closing the gap between CBD's pharmacological potential and its bioavailability could transform it from a wellness trend into a legitimate therapeutic platform.
Questions still open
- Would nano-formulated CBD products show efficacy in conditions where standard CBD formulations have failed?
- Could mucosal delivery bypass the first-pass metabolism that limits oral CBD effectiveness?
Common questions
Why doesn't CBD always work when taken orally?
Could better CBD formulations make a difference?
Read the original research
Cannabidiol - Help and hype in targeting mucosal diseases.
Journal of controlled release : official journal of the Controlled Release Society, 365, 530-543
Citation
Moniruzzaman, Md; Janjua, Taskeen Iqbal; Martin, Jennifer H; Begun, Jakob; Popat, Amirali. (2024). Cannabidiol - Help and hype in targeting mucosal diseases.. Journal of controlled release : official journal of the Controlled Release Society, 365, 530-543. https://doi.org/10.1016/j.jconrel.2023.11.010
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk